Retatrutide, a novel dual activator of the GLP-1 binding site and glucose-dependent insulinotropic polypeptide (GIP) target, is showing promising outcomes in initial patient studies. Recent inquiry https://socialbuzztoday.com/story6856584/retatrutide-emerging-investigations-and-projected-medical-applications